On June 30, Sichuan Orienter Biotechnology Co., Ltd. and InTec PRODUCTS INC. applied for the Growth Enterprise Market and was accepted by Shenzhen Stock Exchange.

ORIENTER in CACLP 2021

Sichuan Orienter Biotechnology Co., Ltd. was established in 2006. Its main business is engaged in the research and development, production and sales of in vitro diagnostic instruments, reagents and consumables, as well as the agency business of non-self-produced in vitro diagnostic products. Meanwhile, it focuses on the medical testing, providing the automated testing solutions and the diagnostic products.

The company began to develop automated inspection instruments and supporting diagnostic products in 2010. After more than 10 years of research and development, it has established an automated diagnostic instrument technology platform and a colloidal gold POCT diagnosis, biochemical diagnosis, magnetic particle chemiluminescence diagnosis and other technical platforms, which are based on the above platforms completed the development of a fully enclosed automated stool analyzer, a fully automatic chemiluminescence immunoassay analyzer, a sample collection and transmission system, a fully automated biochemical immune inspection assembly line, and formed the advantages of automated inspection technology and continuous improvement in the business areas of stool inspection and biochemical immune inspection Diagnostic product lineage.

InTec PRODUCTS INC. was established in 1989, specializing in research and development, production, and marketing of in vitro diagnostic reagents. InTec PRODUCTS INC. is also the Xiamen key industrial enterprise, advanced industrial enterprise of technological progress, and key enterprise of strategic emerging industry in Fujian province.

After 30 years of accumulation and precipitation, core technology platforms have been formed, such as POCT instant diagnosis, enzyme-linked immunological diagnosis, chemiluminescence immunodiagnosis, biochemical diagnosis and fluorescent nucleic acid detection.

As of April 30, 2021, the company has obtained 127 product registration certificates, covering infectious diseases, blood types, respiratory tract, digestive tract, cardiac markers, prenatal and postnatal care, drug abuse and immune diseases in clinical applications. The company’s main products are POCT rapid diagnostic reagents and enzyme-linked immunological diagnostic reagents. In recent years, the company has actively deployed molecular diagnostics and chemiluminescence products to further enrich and improve the existing product line.